US20050186284A1 - Taste-masking oral dosage form and method of preparing the same - Google Patents
Taste-masking oral dosage form and method of preparing the same Download PDFInfo
- Publication number
- US20050186284A1 US20050186284A1 US10/839,243 US83924304A US2005186284A1 US 20050186284 A1 US20050186284 A1 US 20050186284A1 US 83924304 A US83924304 A US 83924304A US 2005186284 A1 US2005186284 A1 US 2005186284A1
- Authority
- US
- United States
- Prior art keywords
- taste
- dosage form
- oral dosage
- starch
- masking oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A taste-masking oral dosage form. The taste-masking oral dosage form comprises a pharmaceutically active ingredient, and a starch, wherein the pharmaceutically active ingredient is packaged by the starch to form a microparticle. A method of preparing the taste-masking oral dosage form is also disclosed.
Description
- 1. Field of the Invention
- The present invention relates to a pharmaceutical composition, and more specifically to a taste-masking oral dosage form and method of preparing the same.
- 2. Description of the Related Art
- There are various types of oral administrative medicines, such as tablets, capsules, granules, powders, syrups and the like. Orally administrated medicines, however, suffer from many drawbacks. For example, pharmaceutically active ingredients in medicines may leave an unpleasant taste after drug administration.
- Tablets and capsules, for example, may be hard to swallow for the elderly or children. Granules and powders may possibly enter the respiratory tract or lungs. Additionally, dosage of syrups, may be difficult measured, particularly for the elderly or children.
- Therefore, many researches regarding taste-masking oral dosage forms have been undertaken recently to provide a new generation rapidly dissolved and safely swallowed tablets, and their dosages can be accurately measured, particularly can mask bitter. Additionally, tablets should possess adequate hardness to facilitate the packaging process.
- Several related arts are disclosed in the following. U.S. Pat. No. 5,804,212 describes a preparation in which a starch and a nasal drug are blended to form a microparticle to improve nasal absorption. European Patent No. 230264 discloses an aqueous nasal drug delivery system for vaccines comprising a high molecular weight drug, a gelling agent such as hydroxyethyl cellulose, and additives such as surfactants or glycerol. The two examples (U.S. Pat. No. 5,804,212 and European Patent No. 230264) merely cite how to improve drug absorption effects, without commenting on taste-masking effects.
- Japanese Patent Laid-open No. 76420/1977 and 24410/1983 describe a method of preparing a porous tablet which comprises blending a tablet-constituting composition with inert solvent, solidifying, compressing the resulting solid into tablets, and evaporating solvent by freeze-drying. U.S. Pat. No. 5,501,861 discloses a method of preparing a fast dissolving tablet comprising a water-soluble saccharide (such as sugar, starch, lactose, sugar alcohol, or tetrose) and a pharmacologically active ingredient, which comprises compressing the blended solid into tablets with a molding pressure of 5˜130 kg/cm2 and evaporating the solvent by freeze-drying.
- The above fast dissolving tablets are prepared by Zydis (from R. P. Scherer, England) freeze-drying. This method, however, suffer from high process cost and insufficient mechanical strength of the preparation.
- Therefore, it is necessary to develop a preparation which offers a pleasant taste and acceptable disintegration speed in an oral cavity after dosage, and possesses a sufficient mechanical strength so as to protect the preparation from destruction in the course of manufacture.
- In order to solve the conventional problems, an object of the invention is to provide an oral dosage form having taste-masking effects, rapid disintegration rates, sufficient hardness to resist destruction during the course of manufacture and storage, and low cost.
- To achieve the above objects, the invention provides a taste-masking oral dosage form comprising a pharmaceutically active ingredient, and a starch, wherein the pharmaceutically active ingredient is packaged by the starch to form a microparticle. The tablet further comprises a hydrophilic polymer, a surfactant, excipicents, or combinations thereof.
- The tablet provided in the invention may be rapidly dissolved in an oral cavity, due to the hydrophilic polymer having strong water absorption, so that it can be advantageously used for treatment of diseases in the elderly or children. Additionally, the dissolution rate of the tablet is improved by the surfactant in an oral cavity, particularly for very slightly dissolved drugs.
- Another object of the invention is to provide a method of preparing a taste-masking oral dosage form, comprising the following steps. A first solution comprising a pharmaceutically active ingredient and a starch is provided. A second solution comprising a hydrophilic polymer and a surfactant is then provided. Subsequently, the first and second solutions are blended to form a plurality of microparticles by a granulating, and a compression-molding process is performed to form the tablet.
- The tablet has an adequate hardness and rapid dissolving rate, due to the specific granulation and additives thereof. More particularly, the bitter taste is wasted, because the pharmaceutically active ingredient is packaged by the starch. Additionally, the low-cost compression-molding process satisfies industry requirements.
- A detailed description is given in the following embodiments with reference to the accompanying drawings.
- The present invention can be more fully understood by reading the subsequent detailed description and examples with references made to the accompanying drawings, wherein:
-
FIG. 1 is a flow chart of the granulating process of the invention. -
FIG. 2 shows the microparticle structure prepared by the invention. -
FIG. 3 is a flow chart of the compression-molding process of the invention. -
FIG. 1 andFIG. 2 illustrate the method of preparing the taste-masking oral dosage form according to the embodiment of the invention. First, referring toFIG. 1 , a first solution is provided in step S10. The first solution comprises solute comprising a pharmaceutically active ingredient and a starch and solvent comprising water or ethanol, wherein the pharmaceutically active ingredient comprises any optional orally administrated drugs, and the starch comprises amylodextrin, hydroxyethyl starch, hydropropyl starch, carboxymethyl starch, acetylated starch, or phosphorylated starch. The uniform and viscous first solution is prepared by heating after blending. - The pharmaceutically active ingredient may be at least one member selected from the group: (1) vitamins, for example, vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12, or vitamin C, minerals, for example, Ca, Mg, Fe, or protein, and amino acid or oligosaccharide and the like.
- (2) antipyretic-analgesic-antiinflammatory agents, for example, aspirin, acetaminophen, ethenzamide, ibuprofen, diphenhydramine hydrochloride, dl-chorpheniramine maleate, dihydrocodeine phosphate, noscapine, methylephedrine hydrochloride, phenylpropanolamine hydrochloride, caffeine, serratiopeptidase, lysozyme chloride, tolfenamic acid, mefenamic acid, diclofenac sodium, flufenamic acid, salicylamide, aminopyrine, ketoprofen, indomethacin, bucolome, or pentazocine and the like.
- (3) antipsychotic drugs, for example, chlorpromazine, reserpine, chlordiazepoxide, diazepam, imipramine, maprotiline, amphetamine, estazolam, nitrazepam, diazepam, phenobarbital sodium, scopolamine hydrobromide, diphenhydramine hydrochloride, or papaverine hydrochloride and the like.
- (4) gastrointestinal function conditioning agents, for example, magnesium carbonate, sodium hydrogen carbonate, magnesium aluminometasilicate, synthetic hydrotalcite, precipitated calcium carbonate, or magnesium oxide and the like.
- (5) antitussive-expectorants, for example, chloperastine hydrochloride, dextromethorphan hydrobromide, theophylline, potassium guaiacolsulfonate, guaifenesin, oxytetracycline, triamcinolone acetonide, chlorhexidine hydrochloride, or lidocaine and the like.
- (6) antihistamines, for example, diphenhydramine hydrochloride, promethazine, isothipendyl hydrochloride, or dl-chlorpheniramine maleate and the like.
- (7) cardiotonics, for example, etilefrine hydrochloride, procainamide hydrochloride, propranolol hydrochloride, pindolol, isosorbide, furosemide, delapril hydrochloride, captopril, hexamethonium bromide, hydralazine hydrochloride, labetalol hydrochloride, or methyldopa and the like.
- (8) vasoconstrictors, for example, phenylephrine hydrochloride, carbocromen hydrochloride, molsidomine, verapamil hydrochloride, cinnarizine, dehydrocholic acid, or trepibutone and the like.
- (9) antibiotics, for example, cephems, penems, carbapenems, cefalexin, amoxicillin, pivmecillinam hydrochloride, or cefotiam dihydrochloride and the like.
- (10) chemotherapeutic drugs, for example, sulfamethizole or thiazosulfone and the like.
- (11) antidiabetic agents, for example, tolbutamide or voglibose and the like.
- (12) drugs for osteoporosis, for example, ipriflavone and the like.
- (13) skeletal muscle relaxants, for example, methocarvamol and the like.
- Subsequently, a second solution is provided S12. The second solution comprises solute comprising a hydrophilic polymer and a surfactant and solvent comprising water or ethanol, wherein the hydrophilic polymer comprises PEG, PVP, carbopol, polysaccharide, agar, MC, or HPMC, and the surfactant comprises edible surfactants comprising phospholipid.
- Next, the first and second solutions are blended in step S14 and continuously stirred to drop the temperature to lower than room temperature. Sediments comprising a plurality of co-crystal microparticles comprising the pharmaceutically active ingredient and the starch may form after cooling, wherein the pharmaceutically active ingredient is packaged by the starch with the package percentage exceeding 95% to isolate the bitter taste, and the diameter of the microparticle is about 150˜360 μm, as shown in
FIG. 2 . Subsequently, the sediments are filtered in step S16, dried in step S18 and sieved in step S20. The granulating process comprises dry granulating, wet granulating, fluidized bed granulating, or spray granulating. - Next, referring to
FIG. 3 , microparticles and excipients are blended in step S22. The excipients comprises disintegrating agents, effervescent agents, sweeteners, and lubricants comprising saccharide, alcohol, and sugar alcohol, wherein saccharide comprises monosaccharide or disaccharide, and sugar alcohol comprises mannitol, sorbitol, xylitol, or glycerol. - Subsequently, the mixture of microparticles and the excipients is sieved in step S24. After sieving, the mixture is compression-molded in step S26 with a tabletting machine, for example, a High-Speed Rotary Tabletting Machine.
- The molding pressure of the High-Speed Rotary Tabletting Machine is about 800˜1200 lb/cm2, and preferably 1000 lb/cm2. The molding speed thereof is about 15˜20 rpm, and preferably 16 rpm.
- The taste-masking oral dosage form of the invention comprises a pharmaceutically active ingredient in a proportion is generally about 35˜45% by weight, a starch in a proportion is generally about 20˜30% by weight, a hydrophilic polymer in a proportion is generally about 2˜10% by weight, a surfactant in a proportion is generally about 2˜10% by weight, and excipients in a proportion are generally about 40˜50% by weight. Additionally, the porosity of the tablet is about 30˜70%, the disintegration time (the time required to complete dissolution by saliva in an oral cavity in a healthy adult male) thereof is less than 1 min, the hardness thereof is about 20˜50 NT, and the brittleness thereof is less than 2%. Specifically, the pharmaceutically active ingredient is packaged with starch with the package percentage exceeding 95% to isolate the bitter taste.
- A first solution comprising acetaminophen (antipyretic-analgesic-antiinflammatory agents), amylodextrin, and H2O was prepared as described in the following steps. First, 400 g of acetaminophen and 84 g of amylodextrin were added into 1600 ml of H2O, stirred, and the first solution was heated to 90° C.
- Subsequently, a second solution comprising a PEG6000 (hydrophilic polymer), lecithin (surfactant), and H2O was prepared as the following step. First, 50 g of PEG6000 and 50 g of lecithin were added into 790 ml of heated H2O at 70° C., and stirred to dissolve completely.
- Next, a wet granulating process was performed, wherein the first solution was slowly added into the second solution, and continuously stirred to drop the temperature to lower than room temperature during blending. Sediments comprising a plurality of co-crystal microparticles comprising the pharmaceutically active ingredient and the starch was formed after cooling, wherein the pharmaceutically active ingredient is packaged by the starch with the package percentage exceeding 95% to isolate the bitter taste, and the diameter of the microparticle is about 150˜360 μm. Subsequently, sediments were filtered through the Buchner funnel, and dried in a dryer at 45° C. Then, sediments were sifted through a sieve with 400 μm diameter mesh.
- Next, microparticles and excipients were blended with a V-shaped blender. The excipients comprises 250 g of lactose (disaccharide), 100 g of mannitol (sugar alcohol), and 100 g of crospovidone (disintegrating agents). Subsequently, the blend was sifted through a sieve with 200 μm diameter mesh. Finally, 400 g of the blend was compression-molded to form a tablet with a High-Speed Rotary Tabletting Machine. The molding pressure was about 1000 lb/cm2, and the molding speed was about 15.9 rpm.
- In this example, 400 g of acetaminophen in a proportion is generally about 40% by weight, 50 g of amylodextrin in a proportion is generally about 5% by weight, 50 g of PEG6000 in a proportion is generally about 5% by weight, 50 g of lecithin in a proportion is generally about 5% by weight, and 450 g of excipients comprising 250 g of lactose, 100 g of mannitol, and 100 g of crospovidone in a proportion are generally about 25% by weight.
- To illustrate the effects of the invention in further detail, the following characteristics of the tablets prepared in the foregoing example was determined, comprising disintegration time, hardness, and brittleness. The results are shown in Table 1.
- The disintegration time of each tablet was determined in accordance with the disintegration test as described in the following. First, 37±2° C., proper amount of water used as solvent was added into the container of the test machine (PHARMA TEST PTZ1 E type). Next, six tablets were added into the container, and the container was covered by a plastic cover. Subsequently, the test machine shook the container until the tablets were disintegrated completely. The mean of the results of six determinations of each pharmaceutically active ingredient was adopted respectively.
- The hardness of each tablet was determined in accordance with the hardness test as described in the following. First, six tablets were placed on the hardness tester (SHIN KWANG SK-32060 type). Next, pressure was applied from the long axis until the tablets were cracked. The mean of the results of six determinations of each pharmaceutically active ingredient was adopted respectively.
- The brittleness of each tablet was determined in accordance with the brittleness test as described in the following. First, 6˜6.5 g of sixteen tablets (380˜420 mg/per tablet) were placed on the sieve (10 mesh). After dropped powders were removed, the precise sample weight (As) was measured. The sample was then added into the test machine (PHARMA TEST PTFE type), and the test machine spun at a speed of 25 rpm for 100 turns. After the sample was taken out, all dropped powders were removed again. Finally, the precise sample weight (A0) was measured. As a result, Brittleness=(A0/As)*100. The mean of the results of sixteen determinations of each pharmaceutically active ingredient was adopted respectively.
TABLE 1 Pharmaceutically Disintegration Hardness brittleness active ingredient time (sec) (NT) (%) acetaminophen 20 ± 5 24.9 ± 7.0 1.2 - The results of Table 1 indicate that the disintegration time of the oral dosage forms of the present invention is less than 1 min, and the brittleness thereof is less than 2%. Therefore, the elderly, children, or those with impaired swallowing ability are able to swallow the tablets, due to rapid disintegration and absorption in an oral cavity. Additionally, an adequate mechanical strength of 20˜50 NT is obtained, facilitating the packaging process in production lines.
- While the invention has been described by way of example and in terms of the preferred embodiments, it is to be understood that the invention is not limited to the disclosed embodiments. To the contrary, it is intended to cover various modifications and similar arrangements (as would be apparent to those skilled in the art). Therefore, the scope of the appended claims should be accorded the broadest interpretation so as to encompass all such modifications and similar arrangements.
Claims (44)
1. A taste-masking oral dosage form, comprising:
a pharmaceutically active ingredient; and
a starch, wherein the pharmaceutically active ingredient is packaged by the starch to form a microparticle;.
2. The taste-masking oral dosage form as claimed in claim 1 , wherein the pharmaceutically active ingredient comprises any optional orally administrated drugs.
3. The taste-masking oral dosage form as claimed in claim 1 , wherein the starch comprises amylodextrin, hydroxyethyl starch, hydropropyl starch, carboxymethyl starch, acetylated starch, or phosphorylated starch.
4. The taste-masking oral dosage form as claimed in claim 1 , wherein the package percentage exceeds 95%.
5. The taste-masking oral dosage form as claimed in claim 1 , wherein the microparticle is a co-crystal structure comprising the pharmaceutically active ingredient and the starch.
6. The taste-masking oral dosage form as claimed in claim 1 , wherein the diameter of the microparticle is about 150˜350 μm.
7. The taste-masking oral dosage form as claimed in claim 1 , wherein the tablet further comprises a hydrophilic polymer, a surfactant, excipients, or combinations thereof.
8. The taste-masking oral dosage form as claimed in claim 7 , wherein the hydrophilic polymer comprises PEG, PVP, carbopol, polysaccharide, agar, MC, or HPMC.
9. The taste-masking oral dosage form as claimed in claim 7 , wherein the surfactant comprises edible surfactants.
10. The taste-masking oral dosage form as claimed in claim 7 , wherein the surfactant comprises lecithin.
11. The taste-masking oral dosage form as claimed in claim 7 , wherein the excipient comprises disintegrating agents, effervescent, lubricants, or sweeteners.
12. The taste-masking oral dosage form as claimed in claim 7 , wherein the excipient comprises saccharide, alcohol, or sugar alcohol.
13. The taste-masking oral dosage form as claimed in claim 12 , wherein saccharide comprises monosaccharide or disaccharide.
14. The taste-masking oral dosage form as claimed in claim 12 , wherein sugar alcohol comprises mannitol, sorbitol, xylitol, or glycerol.
15. The taste-masking oral dosage form as claimed in claim 1 , wherein the pharmaceutically active ingredient in a proportion is generally about 5˜45% by weight.
16. The taste-masking oral dosage form as claimed in claim 1 , wherein the starch in a proportion is generally about 20˜30% by weight.
17. The taste-masking oral dosage form as claimed in claim 7 , wherein the hydrophilic polymer in a proportion is generally about 2˜10% by weight.
18. The taste-masking oral dosage form as claimed in claim 7 , wherein the surfactant in a proportion is generally about 2˜10% by weight.
19. The taste-masking oral dosage form as claimed in claim 7 , wherein the excipient in a proportion is generally about 40˜50% by weight.
20. The taste-masking oral dosage form as claimed in claim 1 , wherein the porosity of the tablet is about 30˜70%.
21. The taste-masking oral dosage form as claimed in claim 1 , wherein the brittleness of the tablet is less than 2%.
22. A method of preparing a taste-masking oral dosage form, comprising:
providing a first solution comprising a pharmaceutically active ingredient and a starch;
providing a second solution comprising a hydrophilic polymer and a surfactant;
blending the first and second solution to form a plurality of microparticles by a granulating process; and
performing a compression-molding process to form the tablet.
23. The method as claimed in claim 22 , wherein the pharmaceutically active ingredient comprises any optional orally administrated drugs.
24. The method as claimed in claim 22 , wherein the starch comprises amylodextrin, hydroxyethyl starch, hydropropyl starch, carboxymethyl starch, acetylated starch, or phosphorylated starch.
25. The method as claimed in claim 22 , wherein the package percentage exceeds 95%.
26. The method as claimed in claim 22 , wherein the microparticle is a co-crystal structure comprising the pharmaceutically active ingredient and the starch.
27. The method as claimed in claim 22 , wherein the diameter of the microparticle is about 150˜350 μm.
28. The method as claimed in claim 22 , wherein the hydrophilic polymer comprises PEG, PVP, carbopol, polysaccharide, agar, MC, or HPMC.
29. The method as claimed in claim 22 , wherein the surfactant comprises edible surfactants.
30. The method as claimed in claim 22 , wherein the surfactant comprises lecithin.
31. The method as claimed in claim 22 , after the first and second solution is blended, further comprising adding excipients into the blended solution.
32. The method as claimed in claim 31 , wherein the excipient comprises disintegrating agents, effervescent, lubricants, or sweeteners.
33. The method as claimed in claim 31 , wherein the excipient comprises saccharide, alcohol, or sugar alcohol.
34. The method as claimed in claim 33 , wherein saccharide comprises monosaccharide or disaccharide.
35. The method as claimed in claim 33 , wherein sugar alcohol comprises mannitol, sorbitol, xylitol, or glycerol.
36. The method as claimed in claim 22 , wherein a molding pressure of the compression-molding is about 800˜1200 lb/cm2.
37. The method as claimed in claim 22 , wherein a molding speed of the compression-molding is about 15˜20 rpm.
38. The method as claimed in claim 22 , wherein the pharmaceutically active ingredient in a proportion is generally about 5˜45% by weight.
39. The method as claimed in claim 22 , wherein the starch in a proportion is generally about 20˜30% by weight.
40. The method as claimed in claim 22 , wherein the hydrophilic polymer in a proportion is generally about 2˜10% by weight.
41. The method as claimed in claim 22 , wherein the surfactant in a proportion is generally about 2˜10% by weight.
42. The method as claimed in claim 31 , wherein the excipient in a proportion is generally about 40˜50% by weight.
43. The method as claimed in claim 22 , wherein the porosity of the tablet is about 30˜70%.
44. The method as claimed in claim 22 , wherein the brittleness of the tablet is less than 2%.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/896,753 US8226981B2 (en) | 2004-02-25 | 2007-09-05 | Method of preparing a taste-masking oral dosage form |
US12/457,151 US20090246288A1 (en) | 2004-02-25 | 2009-06-02 | Taste-masking oral dosage form and method of preparing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW93104745 | 2004-02-25 | ||
TW093104745A TWI335227B (en) | 2004-02-25 | 2004-02-25 | Pharmaceutical composition of taste masking and rapidly dissolving drug and method of preparing the same |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/896,753 Division US8226981B2 (en) | 2004-02-25 | 2007-09-05 | Method of preparing a taste-masking oral dosage form |
US12/457,151 Continuation-In-Part US20090246288A1 (en) | 2004-02-25 | 2009-06-02 | Taste-masking oral dosage form and method of preparing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050186284A1 true US20050186284A1 (en) | 2005-08-25 |
Family
ID=34859737
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/839,243 Abandoned US20050186284A1 (en) | 2004-02-25 | 2004-05-06 | Taste-masking oral dosage form and method of preparing the same |
US11/896,753 Active 2025-10-03 US8226981B2 (en) | 2004-02-25 | 2007-09-05 | Method of preparing a taste-masking oral dosage form |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/896,753 Active 2025-10-03 US8226981B2 (en) | 2004-02-25 | 2007-09-05 | Method of preparing a taste-masking oral dosage form |
Country Status (2)
Country | Link |
---|---|
US (2) | US20050186284A1 (en) |
TW (1) | TWI335227B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011112922A2 (en) * | 2010-03-11 | 2011-09-15 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical formulations comprising the same |
US11464741B2 (en) * | 2014-06-11 | 2022-10-11 | SpecGx LLC | Spray dried compositions having different dissolution profiles and processes for their preparation |
CN104223337A (en) * | 2014-09-09 | 2014-12-24 | 孙国强 | Application method of agar in drop pill shaping |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5082667A (en) * | 1988-06-07 | 1992-01-21 | Abbott Laboratories | Solid pharmaceutical dosage in tablet triturate form and method of producing same |
US5501861A (en) * | 1992-01-29 | 1996-03-26 | Takeda Chemical Industries, Ltd. | Fast dissolving tablet and its production |
US5607697A (en) * | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
US5804212A (en) * | 1989-11-04 | 1998-09-08 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US6024981A (en) * | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
DE3601923A1 (en) | 1986-01-23 | 1987-07-30 | Behringwerke Ag | NASAL APPLICABLE MEDICINE, METHOD FOR THE PRODUCTION AND USE THEREOF |
US5160745A (en) | 1986-05-16 | 1992-11-03 | The University Of Kentucky Research Foundation | Biodegradable microspheres as a carrier for macromolecules |
US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
US6129366A (en) * | 1998-07-10 | 2000-10-10 | Wenger Corporation | Mobile teaching station |
DE60016381T2 (en) | 1999-02-15 | 2005-12-15 | Sumitomo Pharmaceuticals Co., Ltd. | IN THE ORAL AREA FAST-FALLING TABLETS |
EP1034826A1 (en) | 1999-03-05 | 2000-09-13 | Reuter Chemische Apparatebau | Co-crystallization process |
TW561057B (en) | 1999-06-29 | 2003-11-11 | Takeda Chemical Industries Ltd | Orally rapidly disintegrable tablet capabling of reducing the bitterness |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6884436B2 (en) * | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
-
2004
- 2004-02-25 TW TW093104745A patent/TWI335227B/en active
- 2004-05-06 US US10/839,243 patent/US20050186284A1/en not_active Abandoned
-
2007
- 2007-09-05 US US11/896,753 patent/US8226981B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5082667A (en) * | 1988-06-07 | 1992-01-21 | Abbott Laboratories | Solid pharmaceutical dosage in tablet triturate form and method of producing same |
US5804212A (en) * | 1989-11-04 | 1998-09-08 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5501861A (en) * | 1992-01-29 | 1996-03-26 | Takeda Chemical Industries, Ltd. | Fast dissolving tablet and its production |
US5607697A (en) * | 1995-06-07 | 1997-03-04 | Cima Labs, Incorporated | Taste masking microparticles for oral dosage forms |
US6024981A (en) * | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
Also Published As
Publication number | Publication date |
---|---|
TW200528128A (en) | 2005-09-01 |
TWI335227B (en) | 2011-01-01 |
US8226981B2 (en) | 2012-07-24 |
US20080003297A1 (en) | 2008-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9730896B2 (en) | Orally disintegrating tablets and methods of manufacture | |
US6740339B1 (en) | Quickly disintegrating solid preparations | |
US6248357B1 (en) | Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility | |
KR101554374B1 (en) | Orally disintegrating tablet | |
US10117831B2 (en) | Soft chew pharmaceutical formulations | |
JP5594285B2 (en) | Orally disintegrating tablets | |
JP2006070046A (en) | Quick disintegrable solid preparation | |
US7771745B2 (en) | Fast dissolving tablet and method of preparing the same | |
ES2944132T3 (en) | Orodispersible tablet containing fine particles of hydroxyalkylcellulose | |
EP1589950A1 (en) | Methods for making pharmaceutical dosage forms containing active cushioning components | |
US8226981B2 (en) | Method of preparing a taste-masking oral dosage form | |
US20060018961A1 (en) | Compression formed preparation and method for manufacturing same | |
US20100055179A1 (en) | Composition of and Method for Preparing Orally Disintegrating Tablets Containing a High Dose of Pharmaceutically Active Ingredients | |
WO2018124062A1 (en) | Production method for formulation having improved content uniformity | |
JP2016204260A (en) | Production method of tablet | |
US20090246288A1 (en) | Taste-masking oral dosage form and method of preparing the same | |
JP2002154988A (en) | Disintegrable tablet in oral cavity and method for producing the same | |
JP2008133294A (en) | Tablet disintegrated in buccal cavity | |
JP2008280316A (en) | Tablet for oral administration | |
EP4178549A1 (en) | Swellable oral pharmaceutical compositions | |
WO2002092058A1 (en) | Rapidly disintegratable solid preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PHARMACEUTICAL INDUSTRY TECHNOLOGY AND DEVELOPMENT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YANG, CHIH-CHIANG;WANG, WEN-CHE;CHEN, HUI-YU;REEL/FRAME:015307/0733;SIGNING DATES FROM 20040405 TO 20040406 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |